Outcome trials of COX-2 selective inhibitors: global safety evaluation does not promise benefits. (Q35108309)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12698301%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

title

Outcome trials of COX-2 selective inhibitors: global safety evaluation does not promise benefits (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12698301%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

author

Antonio J Carcas Sansuán

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12698301%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

author name string

Jorge Gomez Cerezo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12698301%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Rubin Lubomirov Hristov

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12698301%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Juan J Vázquez Rodríguez

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12698301%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

publication date

16 April 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12698301%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Clinical Pharmacology

2 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12698301%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

volume

59

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12698301%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12698301%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

page(s)

169-175

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12698301%20AND%20SRC:MED&resulttype=core&format=json

Recent considerations in nonsteroidal anti-inflammatory drug gastropathy

2 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0579-1

Nonsteroidal anti-inflammatory drug-related gastrointestinal toxicity: definitions and epidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0579-1

Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0579-1

Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0579-1

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0579-1

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0579-1

Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0579-1

Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy M

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0579-1

Preparing for the PLAB test

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0579-1

Are selective COX 2 inhibitors superior to traditional NSAIDs? Rofecoxib did not provide unequivocal benefit over traditional NSAIDs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0579-1

Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0579-1

Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0579-1

Efficacy and safety of COX 2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0579-1

Misoprostol in patients taking non-steroidal anti-inflammatory drugs. Analysis excluded in important events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0579-1

Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0579-1

Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0579-1

Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0579-1

COX-1-sparing NSAIDs--is the enthusiasm justified?

21 January 2018

1 reference

12 December 2020

Are selective COX 2 inhibitors superior to traditional NSAIDs? Pharmacia's response to editorial

1 reference

12 December 2020

Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs

1 reference

12 December 2020

Initial patterns of use of COX-2 inhibitors by elderly patients in Ontario: findings and implications.

1 reference

12 December 2020

The double-edged sword of COX-2 selective NSAIDs

1 reference

12 December 2020

A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis

1 reference

12 December 2020

Completeness of reporting trial results: effect on physicians' willingness to prescribe

1 reference

12 December 2020

Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor.

1 reference

12 December 2020

10.1007/S00228-003-0579-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12698301%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference